Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB)
AB Science is a late-stage biotech advancing masitinib, an oral, selective tyrosine kinase inhibitor designed to modulate maladaptive neuroinflammation through mast-cell and microglia/macrophage pathways. The Company is positioning masitinib as an add-on therapy across ALS, progressive MS, and AD, while maintaining earlier-stage upside through AB8939 in AML. The combination of a treatment for ALS along […]
Stonegate Capital Partners Initiates Research Coverage on Cassiar Gold Corp. (TSXV: GLDC)
Cassiar’s technical foundation has advanced materially, culminating in a June 2025 NI 43-101 technical report and updated mineral resource estimate for the Cassiar Gold Property. The pit-constrained Taurus MRE outlines Indicated Mineral Resources of 8.8 Mt at 1.43 g/t Au (410 koz) plus Inferred Mineral Resources of 63.2 Mt at 0.95 g/t Au (1.93 Moz) […]
Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings Inc. (NASDAQ: NTHI)
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company developing central nervous system therapeutics designed to overcome the blood–brain barrier. The Company has numerous assets in its pipeline, highlighted by NEO100 which is a patented, pure pharmaceutical compound produced via proprietary synthesis for pharmaceutical-grade purity and reproducibility. NeOnc’s intranasal administration strategy is designed to […]
Stonegate Capital Partners Updates Coverage Initiates Report on Viemed Healthcare Inc. (NASDAQ: VMD)
Viemed Healthcare is the leading U.S. provider of in-home post-acute respiratory care, specializing in non-invasive ventilation (“NIV”) for patients with COPD and chronic respiratory failure. The Company delivers care through a clinician-driven, high-touch model that integrates respiratory therapists, proprietary clinical workflows, and continuous patient monitoring to improve outcomes and reduce total cost of care. While […]
Stonegate Capital Partners Initiates Coverage on ARMOUR Residential REIT Inc. (NYSE: ARR)
The Company ended the quarter with revenues, net income to common, and diluted EPS of $210.2M, $156.3M, and $1.49. This was a year over year increase of 65.4%, 148.5% and 23.2% respectively. This was primarily driven by the strong growth in average interest income on interest earning assets while interest cost on average interest-bearing liabilities […]
Stonegate Capital Partners Initiates Coverage on Fold Holdings Inc. (NASDAQ: FLD)
Fold delivered revenue of $7.4M, net income of $0.6M, and adj EBITDA of $(4.2)M as legacy products continued to scale. Operating KPIs moved in tandem as the Company saw $265M in total transaction volume for the quarter, 10K+ net new accounts, and 3K+ new verified accounts. New accounts rose 2.1% y/y while transaction volumes climbed […]
Stonegate Capital Partners Initiates Coverage on Vinte Viviendas Integrales (BMV: VINTE)
VINTE reported total revenue of MXN 3.66B, up 211.3% y/y, driven by the Javer acquisition. Compared to pro forma 2Q24 revenue, VINTE would have seen a 6.8% decrease. Average selling prices increased 11.8% to $975,000, up from $872,000 last year. Consolidated EBITDA reached $647.6M, up 124.7% y/y and down 16.4% on a pro forma basis, […]
Stonegate Capital Partners Initiates Coverage on Pensana PLC (LSE: PRE)
Pensana is one of the few developers outside China pursuing a full mine-to-magnet model, capturing value across the rare earth supply chain. Rather than relying on a “dig-and-ship” approach, the Company is advancing a U.S.-facing downstream strategy that aligns with Western supply chain security goals. A memorandum of understanding with ReElement Technologies provides a direct […]
Stonegate Capital Partners Initiates Coverage on Heliostar Metals Ltd (TSXV: HSTR)
The Company’s flagship Ana Paula project in Guerrero is a high-grade underground development asset hosting approximately 1.2 million ounces grading 5.4 g/t gold in the High-Grade Panel. Active drilling is extending the Parallel Panel and upgrading inferred ounces. A preliminary economic assessment is underway and will be followed by a feasibility study in mid-2026, with […]
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (NASDAQ: MDCX)